$167.21
-0.04[-0.02%]
At close: Apr 24
$167.21
0[0.00%]
PreMarket: 5:48PM EDT
Insulet
(NASDAQ:PODD)Insulet Stock (NASDAQ:PODD), Analyst Ratings, Price Targets, Predictions
Insulet Corp has a consensus price target of $253.72, established from looking at the 72 latest analyst ratings. The last 3 analyst ratings were released from Barclays, Piper Sandler, and JP Morgan on February 26, 2024, February 23, 2024, and February 23, 2024. With an average price target of $222.67 between Barclays, Piper Sandler, and JP Morgan, there's an implied 33.17% upside for Insulet Corp from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Barclays
Piper Sandler
JP Morgan
Stifel
Baird
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Insulet
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 02/26/2024 | PODD | Buy Now | Insulet | $167.21 | 27.38% | Barclays | Matt Miksic | $214 → $213 | Maintains | Equal-Weight | Get Alert |
| 02/23/2024 | PODD | Buy Now | Insulet | $167.21 | 37.55% | Piper Sandler | Matt O'Brien | $250 → $230 | Maintains | Overweight | Get Alert |
| 02/23/2024 | PODD | Buy Now | Insulet | $167.21 | 34.56% | JP Morgan | Robbie Marcus | $190 → $225 | Maintains | Overweight | Get Alert |
| 02/05/2024 | PODD | Buy Now | Insulet | $167.21 | 24.39% | Stifel | Mathew Blackman | $163 → $208 | Maintains | Hold | Get Alert |
| 12/21/2023 | PODD | Buy Now | Insulet | $167.21 | 42.34% | Baird | Jeff Johnson | $180 → $238 | Upgrade | Neutral → Outperform | Get Alert |
| 12/04/2023 | PODD | Buy Now | Insulet | $167.21 | 39.94% | Morgan Stanley | Patrick Wood | $185 → $234 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 11/03/2023 | PODD | Buy Now | Insulet | $167.21 | 49.51% | Piper Sandler | Matt O'Brien | $325 → $250 | Maintains | Overweight | Get Alert |
| 10/17/2023 | PODD | Buy Now | Insulet | $167.21 | -3.12% | JP Morgan | Robbie Marcus | $325 → $162 | Maintains | Overweight | Get Alert |
| 10/16/2023 | PODD | Buy Now | Insulet | $167.21 | 10.04% | Leerink Partners | Mike Kratky | → $184 | Initiates | → Outperform | Get Alert |
| 10/02/2023 | PODD | Buy Now | Insulet | $167.21 | 43.53% | Jefferies | Matthew Taylor | $260 → $240 | Upgrade | Hold → Buy | Get Alert |
| 09/29/2023 | PODD | Buy Now | Insulet | $167.21 | 10.64% | Morgan Stanley | Patrick Wood | $208 → $185 | Maintains | Equal-Weight | Get Alert |
| 09/15/2023 | PODD | Buy Now | Insulet | $167.21 | 36.36% | Raymond James | Jayson Bedford | $299 → $228 | Maintains | Outperform | Get Alert |
| 09/06/2023 | PODD | Buy Now | Insulet | $167.21 | 28.58% | UBS | Matthew Taylor | $270 → $215 | Maintains | Neutral | Get Alert |
| 08/24/2023 | PODD | Buy Now | Insulet | $167.21 | 76.42% | B of A Securities | Travis Steed | $365 → $295 | Maintains | Buy | Get Alert |
| 08/24/2023 | PODD | Buy Now | Insulet | $167.21 | 24.39% | Morgan Stanley | Patrick Wood | $343 → $208 | Maintains | Equal-Weight | Get Alert |
| 08/21/2023 | PODD | Buy Now | Insulet | $167.21 | 58.48% | Citigroup | Joanne Wuensch | $273 → $265 | Upgrade | Neutral → Buy | Get Alert |
| 08/21/2023 | PODD | Buy Now | Insulet | $167.21 | 30.97% | Baird | Jeff Johnson | $320 → $219 | Downgrade | Outperform → Neutral | Get Alert |
| 08/10/2023 | PODD | Buy Now | Insulet | $167.21 | 53.7% | Barclays | Matt Miksic | $329 → $257 | Maintains | Equal-Weight | Get Alert |
| 08/09/2023 | PODD | Buy Now | Insulet | $167.21 | 79.42% | TD Cowen | Josh Jennings | $350 → $300 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Insulet (PODD)?
The latest price target for Insulet (NASDAQ: PODD) was reported by Barclays on February 26, 2024. The analyst firm set a price target for $213.00 expecting PODD to rise to within 12 months (a possible 27.38% upside). 30 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Insulet (PODD)?
The latest analyst rating for Insulet (NASDAQ: PODD) was provided by Barclays, and Insulet maintained their equal-weight rating.
When was the last upgrade for Insulet (PODD)?
The last upgrade for Insulet Corp happened on December 21, 2023 when Baird raised their price target to $238. Baird previously had a neutral for Insulet Corp.
When was the last downgrade for Insulet (PODD)?
The last downgrade for Insulet Corp happened on August 21, 2023 when Baird changed their price target from $320 to $219 for Insulet Corp.
When is the next analyst rating going to be posted or updated for Insulet (PODD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Insulet, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Insulet was filed on February 26, 2024 so you should expect the next rating to be made available sometime around February 26, 2025.
Is the Analyst Rating Insulet (PODD) correct?
While ratings are subjective and will change, the latest Insulet (PODD) rating was a maintained with a price target of $214.00 to $213.00. The current price Insulet (PODD) is trading at is $167.21, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.